Origenis Extends Collaboration and Licensing Agreement with Major Pharmaceutical Company
News May 02, 2013
The alliance combines Origenis' capabilities in compound design, chemical synthesis, and screening with the collaborator’s applied biology, pharmacology, and development expertise in therapeutics.
During the long standing collaboration, Origenis successfully employed its proprietary small molecule discovery platform MOREsystem® to design, synthesize, and characterize novel molecules acting against different targets. Under the extended agreement, Origenis will deliver development candidates with defined properties for certain targets.
Dr. Michael Thormann, Managing Director at Origenis said: “This new agreement underlines the quality of the compounds transferred in the past and the power of our technology platform as well as our interdisciplinary approach and expertise applied to development compounds and commitment of our company in the small molecule drug sector.”
Under the terms of the agreement, the collaborator will receive rights to develop products against defined molecular targets for any indication. Origenis will receive research payments and is eligible for certain development milestones and also royalties on sales.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019